AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its third quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 3.730-3.770 for the period, compared to the consensus EPS estimate of 3.850. The company issued revenue guidance of -.

AbbVie Stock Performance

NYSE:ABBV opened at $266.65 on Wednesday. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $269.39. The firm has a market cap of $471.11 billion, a PE ratio of 75.32, a price-to-earnings-growth ratio of 1.20 and a beta of 0.24. The business has a 50 day moving average price of $258.12 and a 200-day moving average price of $235.42.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts predict that AbbVie will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Canaccord Genuity Group lifted their price objective on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Morgan Stanley reaffirmed an “overweight” rating and set a $296.00 price target (up from $278.00) on shares of AbbVie in a research report on Monday, August 3rd. Citigroup lifted their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. BMO Capital Markets upped their price objective on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $273.82.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Major lymphoma trial win: AbbVie and Genmab reported that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The Phase 3 EPCORE DLBCL-2 study met its primary progression-free-survival endpoint, prompting plans to engage global regulators. The result could position Epkinly as a frontline competitor to Roche’s Polivy and expand AbbVie’s long-term oncology revenue opportunity. AbbVie and Genmab Announce Epcoritamab Results
• Positive Sentiment: Analysts raise targets: Scotiabank lifted its AbbVie price target from $280 to $320 and reiterated a “sector outperform” rating. HSBC separately outlined a bullish case for a $315 target, citing AbbVie’s growth prospects and drug pipeline. These targets imply meaningful potential appreciation from recent trading levels and helped reinforce positive sentiment. AbbVie Stock Price Target Raised at Scotiabank
• Positive Sentiment: New Parkinson’s treatment: AbbVie’s newly approved pill is described as the first FDA-approved selective D1/D5 drug, adding another potential growth product beyond its established immunology and aesthetics franchises. AbbVie Parkinson’s Pill Approval
• Neutral Sentiment: Upcoming earnings catalyst: AbbVie is scheduled to report third-quarter results on October 30. Analysts broadly rate the shares a Buy, but the elevated valuation means investors will likely focus on execution, pipeline progress and updated guidance. Should You Buy AbbVie Stock Before October 30?
• Negative Sentiment: Lower Q3 earnings guidance: AbbVie now expects third-quarter adjusted EPS of $3.73 to $3.77, below the $3.85 consensus estimate, after recording $216 million in acquired in-process research and development and milestone expenses. Full-year adjusted EPS guidance was also reduced by $0.11 to $13.76-$13.96, creating a near-term earnings overhang. AbbVie Updates 2026 Adjusted EPS Guidance

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.